Back to discover
Drug

Choriogonadotropin alfa

Established medicine
ClassLuteinizing hormone/Choriogonadotropin receptor agonistResearchOngoing clinical research

Also known as Ovidrel, Choriogonadotrophin alfa, Choriogonadotropin alpha.

RxNorm283550ChEMBLCHEMBL1201464ATCG03GA08UNII6413W06WR3
1
Active clinical trials
LHCGR
Primary target
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Choriogonadotropin alfa
Aliases & brands
OvidrelChoriogonadotrophin alfaChoriogonadotropin alpha
RxNorm CUI
283550
ChEMBL ID
CHEMBL1201464
ATC codes
G03GA08
UNII
6413W06WR3
Primary mechanism
Luteinizing hormone/Choriogonadotropin receptor agonist
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Lutropin-choriogonadotropic hormone receptor
LHCGR · P22888
AGONISTLuteinizing hormone/Choriogonadotropin receptor agonist

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2001-02-02
Latest approval
2001-02-02
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2001-02-02Approval
Approval: Ovitrelle (EMA)
Indication: Ovitrelle is indicated in the treatment of: women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Ovitrelle is… Show full indication

Ovitrelle is indicated in the treatment of: women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth; anovulatory or oligo-ovulatory women: Ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

3 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
3
registered trials across all phases
LATEST COMPLETION 2023
1
Active studies
1
Recruiting
2
Late-stage (III+)
1
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 3
Early Phase 11Phase 41Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study

Unknown statusPH IVSheba Medical Centern=622017

Recent completions

Trials that read out recently, adding to the completed evidence base.

Can Biotin Supplementation be Used to Mask hCG Abuse?

CompletedPH ISports Medicine Research and Testing Laboratoryn=102023
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.